Advertisement

Advertisement

Leukemia
Lymphoma
Immunotherapy

Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL

On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...

CNS Cancers
Immunotherapy

Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma

Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...

Lung Cancer
Immunotherapy

Immunotherapy Trials for Metastatic NSCLC: FDA Pooled Analysis

In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Bernardo Haddock Lobo Goulart, MD, and colleagues found that response rate and progression-free survival were only moderately correlated with overall survival in first-line immunotherapy trials for...

Hematologic Malignancies
Immunotherapy

Factors Associated With Myeloid Neoplasms Following CAR T-Cell Therapy

In an analysis reported in a research letter in JAMA Oncology, Gurney et al identified factors associated with an increased risk of myeloid neoplasms after chimeric antigen receptor (CAR) T-cell therapy. Study Details Investigators identified adults who received CAR T-cell therapy between June 2016 ...

Multiple Myeloma
Immunotherapy

Advanced Multiple Myeloma: Prediction Model for Outcomes After BCMA-Directed CAR T-Cell Therapy

As reported in the Journal of Clinical Oncology, Gagelmann et al have developed a predictive model (Myeloma CAR-T Relapse [MyCARe] model) for outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple...

Multiple Myeloma
Immunotherapy

Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

The chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel may offer benefit in patients with multiple myeloma who experienced disease progression or relapse following initial therapy, according to new findings presented by Hillengass et al at the 2024 Tandem Meetings:...

Skin Cancer
Immunotherapy

FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma

On February 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for adult patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody, or, if they have...

Multiple Myeloma
Immunotherapy

STAb T-Cell–Based Immunotherapy in Multiple Myeloma

A novel immunotherapy based on STAb T cells may be more effective at treating multiple myeloma than chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Díez-Alonso et al in Science Translational Medicine. Background Multiple myeloma is the second most common...

Lung Cancer
Immunotherapy

Durvalumab Plus Ceralasertib in Patients With Immunotherapy-Resistant NSCLC

The combination of the anti–PD-L1 antibody durvalumab and the ATR kinase inhibitor ceralasertib may help overcome inherent immune resistance and reinvigorate antitumor activity in patients with advanced non–small cell lung cancer (NSCLC), according to a recent study published by Besse et al in...

Sarcoma
Immunotherapy

Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma

Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer. Background About 13,000 new cases of soft-tissue...

Hematologic Malignancies
Immunotherapy

EBV-Positive Posttransplantation Lymphoproliferative Disease: T-Cell Immunotherapy Efficacy

In the phase III ALLELE trial reported in The Lancet Oncology, Mahadeo et al found that the Epstein-Barr virus (EBV)-specific T-cell immunotherapy tabelecleucel produced high response rates—and few of the toxicities associated with other adoptive T-cell therapies—in allogeneic hematopoietic stem...

kidney cancer
immunotherapy

Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab

Saby George, MD, of Roswell Park Comprehensive Cancer Center, discusses pharmacokinetics, efficacy, and safety results from CheckMate 67T, a phase III trial comparing the use of subcutaneous vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who have received prior systemic therapy (Abstract LBA360).

bladder cancer
immunotherapy

Syed Muneeb Alam, MD, on Urothelial Carcinoma: Microsatellite Instability and Response to Immune Checkpoint Blockade

Syed Muneeb Alam, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings evaluating links among microsatellite instability status, tumor mutational burden, and response to immune checkpoint blockade in patients with microsatellite instability–high urothelial carcinoma (Abstract 536).

Lymphoma
Hematologic Malignancies
Immunotherapy

Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy

Researchers may have uncovered a novel strategy to identify which patients may experience poorer outcomes from chimeric antigen receptor (CAR) T-cell therapy prior to treatment, according to a recent study published by Faramand et al in Blood Cancer Discovery. The findings indicate opportunities to ...

Kidney Cancer
Immunotherapy

Subcutaneous vs Intravenous Nivolumab in Advanced Clear Cell RCC

In previously treated patients with advanced or metastatic clear cell renal cell carcinoma, a subcutaneous formulation of nivolumab was found to be noninferior to the intravenous formulation, which is standard of care for nivolumab in renal cell carcinoma and other cancers. Compared with...

Sarcoma
Immunotherapy
Cardio-oncology

Immunotherapy Outcomes in Patients With Primary Cardiac Soft-Tissue Sarcomas

In a U.S. multicenter retrospective analysis reported in JACC: CardioOncology, Amin H. Nassar, MD, and colleagues found that immune checkpoint inhibition resulted in mostly moderate activity in patients with primary cardiac soft-tissue sarcomas. Study Details The study included 24 patients with...

Bladder Cancer
Immunotherapy

Use of Adjuvant Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma: CheckMate 274

Subsequent systemic therapy with the immune checkpoint inhibitor nivolumab may offer overall survival benefit in patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumors, according to recent findings presented by Geynisman et al at the 2024 ASCO Genitourinary...

Kidney Cancer
Immunotherapy
Issues in Oncology

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

Immune checkpoint inhibitor–based therapy may be an equally effective front-line treatment in both Black and White patients with metastatic renal cell carcinoma, according to recent findings presented by Kaur et al at the 2024 ASCO Genitourinary Cancers Symposium (Abstract 369). Background Race may ...

gastrointestinal cancer
immunotherapy

Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?

Yasunobu Ishizuka, MD, of Japan’s Aichi Cancer Center, discusses study results showing that scheduling infusions of nivolumab monotherapy before mid-afternoon for patients with metastatic gastric cancer may alter treatment efficacy. Several studies have suggested that circadian rhythm is essential in immune system function, including anticancer immunity (Abstract 268).

Issues in Oncology
Immunotherapy

FDA Issues Safety Labeling Change Notification to CAR T-Cell Therapy Manufacturers

On January 19, the U.S. Food and Drug Administration (FDA) issued safety labeling change notification letters to all manufacturers of licensed B-cell maturation antigen (BCMA)-directed and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapies requiring ...

Lung Cancer
Immunotherapy

DXH9 Depletion May Expose Small Cell Lung Cancer Tumors to Immune System Attack

Researchers may have identified a novel genetic mechanism capable of making small cell lung cancer tumors more susceptible to an attack by the immune system, according to a new study published by Murayama et al in Cancer Discovery. The findings could lead to the development of new therapeutics to...

Global Cancer Care
Immunotherapy

Use of Lower-Than-Recommended Doses of Immune Checkpoint Inhibitors in Various Tumor Types: Indian Study

In an Indian single-institution study reported in JCO Global Oncology, Patel et al found that use of lower-than-recommended doses of immune checkpoint inhibitors showed activity across various tumor types. As stated by the investigators: “The cost of immune checkpoint inhibitors limits their...

Immunotherapy
Issues in Oncology

Immunotherapy Initiation at the End of Life for Patients With Metastatic Cancers

In an analysis reported in JAMA Oncology, Kerekes et al found that initiation of immunotherapy at the end of life has increased over time in U.S. patients with metastatic cancers. Study Details The retrospective cohort study used data from the National Cancer Database on patients with stage IV...

Breast Cancer
Immunotherapy

Atezolizumab Plus Carboplatin in Metastatic Triple-Negative Breast Cancer

Researchers have evaluated the efficacy of atezolizumab in combination with carboplatin in patients with triple-negative breast cancer, according to a recent study published by Lehmann et al in JAMA Oncology. The new findings may help researchers better understand biomarkers of immunotherapy...

Lung Cancer
Immunotherapy

Real-World Data Show Impact of Immunotherapy in Populations Underrepresented in Lung Cancer Clinical Trials

New research published by Lee et al in JNCCN—Journal of the National Comprehensive Cancer Network found patients treated with first-line immunotherapy for advanced non–small cell lung cancer (NSCLC) had similar results in terms of overall survival, progression-free survival, and treatment duration, ...

Immunotherapy
Issues in Oncology

New Study Uncovers Factors Potentially Contributing to Development of Colitis in Patients Undergoing Cancer Immunotherapy

Researchers may have uncovered a mechanism contributing to the development of colitis in patients with cancer receiving immunotherapy as well as a novel strategy to deliver immune-based therapy without causing the adverse side effect, according to a recent study published by Lo et al in Science....

leukemia
lymphoma
immunotherapy

Adam S. Kittai, MD, on Richter’s Transformation: Anti-CD19 CAR T-Cell Therapy

Adam S. Kittai, MD, of The Ohio State University, discusses his data supporting the use of CAR T-cell therapy for patients with Richter’s transformation. Given the high response rate to CD19 CAR T-cell treatment, along with early relapse in most patients, allogeneic stem cell transplantation at response should also be considered, he says (Abstract 108).

Skin Cancer
Immunotherapy

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

A rare subset of T cells called V-delta 1 gamma-delta (Vd1-gd) T cells could help predict which patients with advanced skin cancer may be responsive to immunotherapy, according to a novel study published by Davies et al in Nature Cancer. The new findings may lead to the development of new and more...

Immunotherapy
Colorectal Cancer
Gynecologic Cancers

Next-Generation Sequencing May Help Improve Access to Immunotherapy Among Patients With Cancer and Mismatch Repair Deficiency

Next-generation sequencing may help better identify patients with cancer and mismatch repair deficiency who may benefit from immunotherapy, according to a recent study published by Farhat et al in Cancer Cell. The new findings indicated that treating more patients with immunotherapy may require...

Lymphoma
Cost of Care
Immunotherapy

Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy

The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel may be a cost-effective second-line treatment option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Choe et al in Blood Advances. Background In cases...

Colorectal Cancer
Immunotherapy

Can Immunotherapy Induce Sustained Disease Control Among Patients With Colorectal Cancer?

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and the third-leading cause of cancer-related deaths. According to the American Cancer Society, in 2023, it is estimated that about 52,550 individuals died from the...

Gastroesophageal Cancer
Immunotherapy

Novel Antibody-Drug Conjugate Under Study in Treatment of Gastric or Gastroesophageal Junction Cancers

A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may prove to be an effective treatment option for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: November 2023.1 (The ASCO Plenary Series is...

Solid Tumors
Immunotherapy

Adding Immune Checkpoint Inhibitors to Perioperative Treatment for Solid Tumors: Associated Toxicity?

In a systematic review and meta-analysis reported in The Lancet Oncology, Fujiwara et al found that the addition of immune checkpoint inhibitors to perioperative therapy in patients with solid tumors was associated with an increased risk of grade 3 and 4 treatment-related adverse events and adverse ...

Multiple Myeloma
Immunotherapy
Issues in Oncology

Use of Elranatamab for Black Patients With Multiple Myeloma

Elranatamab may be safe and effective in Black patients with relapsed or refractory multiple myeloma, according to new findings presented by Varshavsky-Yanovsky et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 3333). Background Elranatamab—an...

Lymphoma
Immunotherapy

CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins

Data presented at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins (Abstract 615). While the findings do not answer the...

Bladder Cancer
Immunotherapy

Disitamab Vedotin in Previously Treated Patients With Advanced HER2-Positive Urothelial Carcinoma

In a combined analysis of two Chinese phase II trials (RC48-C005 and RC48-C009) reported in the Journal of Clinical Oncology, Sheng et al found that the antibody-drug conjugate disitamab vedotin—an anti-HER2 antibody conjugated with monomethyl auristatin—produced promising results in patients with...

Lung Cancer
Immunotherapy
Issues in Oncology

Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma

The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology. Background Australia...

Issues in Oncology
Immunotherapy

FDA Investigating Risk of T-Cell Malignancy Following BCMA- or CD19-Directed Autologous CAR T-Cell Immunotherapies

The U.S. Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor (CAR)-positive lymphoma, in patients who received treatment with B cell maturation antigen (BCMA)- or CD19-directed autologous CAR T-cell immunotherapies. Reports were...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Amends Pembrolizumab’s Gastric Cancer Indication

On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...

breast cancer
immunotherapy

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer, regardless of pathologic complete response (Abstract LBA18).

lung cancer
immunotherapy

Mark M. Awad, MD, PhD, on NSCLC: Neoadjuvant Nivolumab Plus Ipilimumab vs Chemotherapy

Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings from the CheckMate 816 trial, which showed a potential clinical benefit to neoadjuvant nivolumab plus ipilimumab vs chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) (Abstract 1261O).

Lung Cancer
Immunotherapy

Perioperative Durvalumab in Resectable NSCLC: AEGEAN Trial

As reported in The New England Journal of Medicine by John V. Heymach, MD, PhD, and colleagues, the phase III AEGEAN trial has shown that perioperative durvalumab improved event-free survival and pathologic complete response (pCR) rate in patients with resectable non–small cell lung cancer ...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Addition of First-Line Pembrolizumab to Chemotherapy in HER2-Negative Advanced Gastric Cancer

As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement  in overall survival in patients with HER2-negative advanced...

Hepatobiliary Cancer
Immunotherapy

FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer

On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...

lung cancer
immunotherapy

Ze-rui Zhao, PhD, on Resectable NSCLC: SBRT With Sequential Immunochemotherapy

Ze-rui Zhao, PhD, of China’s Sun Yat-sen University Cancer Center, discusses new phase II findings on stereotactic body radiation therapy (SBRT) with sequential immunochemotherapy as a neoadjuvant treatment of patients with resectable non–small cell lung cancer (NSCLC). This therapy yielded a high major pathologic response rate, according to Dr. Zhao (Abstract LBA60).

Lung Cancer
Immunotherapy

Association of Germline EGFR Mutations With Familial Lung Cancer

In the INHERIT study—reported in the Journal of Clinical Oncology—Geoffrey R. Oxnard, MD, FASCO, and colleagues identified associations between germline EGFR mutations and familial lung cancer. As stated by the investigators, “The genomic underpinnings of inherited lung cancer risk are poorly...

Kidney Cancer
Immunotherapy

Nivolumab With or Without Nivolumab/Ipilimumab Boost in Metastatic Renal Cell Carcinoma

In the phase II TITAN-RCC trial reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy with or without nivolumab/ipilimumab as an immunotherapeutic boost was associated with activity in patients with metastatic clear cell renal cell carcinoma. Study Details In...

lung cancer
immunotherapy

Jonathan D. Spicer, MD, PhD, on Early-Stage NSCLC: Survival Results With Pembrolizumab

Jonathan D. Spicer, MD, PhD, of McGill University, discusses findings from the KEYNOTE-671 study of perioperative pembrolizumab for patients with resectable early-stage non–small cell lung cancer (NSCLC). Neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab improved overall survival compared with neoadjuvant chemotherapy and resection alone in stage II, IIIA, or IIIB (N2) disease (Abstract LBA56).

Genomics/Genetics
Kidney Cancer
Immunotherapy

Two New Studies Using CancerLinQ Data

Two new studies—presented by Drumheller et al and Vento et al at the 2023 ASCO Quality Care Symposium—utilized data from ASCO’s CancerLinQ® database (Abstracts 418 and 532). One study revealed deficiencies in biomarker testing and tracking in electronic health records, and the other analyzed...

Leukemia
Immunotherapy

Sequential CD19- and CD22-Directed CAR T-Cell Therapy in Pediatric B-Cell ALL

In a Chinese single-center phase II study reported in The Lancet Oncology, Pan et al found that sequential CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell therapy was active in pediatric patients with refractory or relapsed B-cell acute lymphocytic leukemia (ALL). Study Details In...

Advertisement

Advertisement

Advertisement